Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 79.7% in December

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 233,417 shares, a decline of 79.7% from the November 30th total of 1,147,847 shares. Based on an average trading volume of 1,100,765 shares, the short-interest ratio is presently 0.2 days. Currently, 1.1% of the shares of the company are sold short. Currently, 1.1% of the shares of the company are sold short. Based on an average trading volume of 1,100,765 shares, the short-interest ratio is presently 0.2 days.

Enlivex Therapeutics Stock Down 3.8%

NASDAQ:ENLV traded down $0.03 on Friday, reaching $0.74. The company’s stock had a trading volume of 287,446 shares, compared to its average volume of 1,166,548. The firm has a market cap of $18.07 million, a price-to-earnings ratio of -1.35 and a beta of 1.49. The stock has a 50 day moving average price of $0.98 and a 200 day moving average price of $1.10. Enlivex Therapeutics has a 12-month low of $0.73 and a 12-month high of $2.10.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. Equities research analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current fiscal year.

Institutional Trading of Enlivex Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Citizens Financial Group Inc. RI purchased a new position in Enlivex Therapeutics in the third quarter valued at approximately $241,000. Susquehanna International Group LLP acquired a new position in shares of Enlivex Therapeutics in the 3rd quarter valued at $57,000. Finally, Jane Street Group LLC boosted its holdings in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares in the last quarter. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ENLV has been the subject of several analyst reports. Wall Street Zen raised Enlivex Therapeutics to a “sell” rating in a report on Saturday, August 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Enlivex Therapeutics in a research report on Tuesday, September 2nd. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. Finally, D Boral Capital lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.